中生制药与康方生物开发肺癌药物派安普利中期分析结果优异

经济通中国站
01 Mar 2021

原标题:中生制药与康方生物开发肺癌药物派安普利中期分析结果优异

  中国生物制药(01177)宣布,集团与康方生物(09926)共同开发的抗PD-1单抗药物「派安普利」联合化疗一线治疗鳞状非小细胞肺癌患者的III期临床试验的中期分析显示出优异结果,达到预期的客观缓解率主要研究终点。

  该项临床试验的安全性数据与已知风险相符,未出现新的安全性问题。

  本次研究中期分析结果经独立数据审核委员会(IDMC)审核,其结果显示,派安普利单抗联合紫杉醇和卡铂对比安慰剂联合紫杉醇和卡铂,可显著降低疾病进展或死亡风险,主要研究终点达到方案预设的优效界值,安全性特徵与既往报道的派安普利单抗研究结果一致,无新的安全性问题。

(文章来源:经济通中国站)

(责任编辑:DF524)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10